文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

可溶性CD73与非脓毒性休克及脓毒性休克患者90天死亡率的交互作用:FINNAKI研究二次分析

[The interaction between soluble CD73 and 90-day mortality from patients with non-septic shock and sepsis shock: a secondary analysis from the prospective FINNAKI study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论在非脓毒性休克与脓毒性休克患者中,sCD73与90天死亡率的关系存在显著差异,方向相反。

该研究为FINNAKI前瞻性观察队列的二次分析,纳入芬兰17个ICU的588例严重脓毒症/脓毒性休克患者。按Sepsis-1定义分为非脓毒性休克159例与脓毒性休克429例;按Sepsis-3定义分为383例与205例。多变量Logistic回归交互检验显示,两种定义下sCD73与90天死亡率的关系在两组间均有显著差异(交互P=0.046和0.027)。非脓毒性休克中sCD73与90天死亡率呈正相关趋势,脓毒性休克中呈负相关趋势,GAM模型验证结果一致。

要点

  • sCD73与90天死亡率的关系在非脓毒性休克与脓毒性休克间存在显著交互作用(Sepsis-1交互P=0.046,Sepsis-3交互P=0.027)。
  • 非脓毒性休克患者中,sCD73与90天死亡率呈正相关趋势(Sepsis-3:OR=1.34,95%CI 1.02-1.74,P=0.034)。
  • 脓毒性休克患者中,sCD73与90天死亡率呈负相关趋势(Sepsis-1:OR=0.91,95%CI 0.69-1.20,P=0.494;Sepsis-3:OR=0.80,95%CI 0.55-1.17,P=0.249)。
  • 按Sepsis-3定义,脓毒性休克90天死亡率显著高于非脓毒性休克(37.56% vs. 22.72%,P<0.01);按Sepsis-1定义则无显著差异。
  • 该关系为观察性关联,不能作为床旁决策阈值,需前瞻性验证。

适用人群与场景

  • FINNAKI研究纳入的芬兰17个ICU的严重脓毒症/脓毒性休克成人患者,共588例。
  • 按Sepsis-1定义分为非脓毒性休克159例和脓毒性休克429例;按Sepsis-3定义分为非脓毒性休克383例和脓毒性休克205例。

诊断标准与关键阈值

  • 脓毒症/脓毒性休克按Sepsis-1定义判定;敏感性分析采用Sepsis-3定义。
  • 原文未提及sCD73的具体检测方法、单位或阈值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:FINNAKI前瞻性观察队列研究的二次分析,芬兰17个ICU,2011年9月1日至2012年2月1日。
  • 样本量:588例严重脓毒症/脓毒性休克患者,90天内死亡164例,90天死亡率27.89%。
  • 主要终点:sCD73与90天死亡率的交互作用。多变量Logistic回归(调整除并发症数量外的所有混杂因素)交互检验:Sepsis-1定义P=0.046,Sepsis-3定义P=0.027。
  • 非脓毒性休克组sCD73与90天死亡率:Sepsis-1 OR=1.46(95%CI 0.99-2.13,P=0.053);Sepsis-3 OR=1.34(95%CI 1.02-1.74,P=0.034)。
  • 脓毒性休克组sCD73与90天死亡率:Sepsis-1 OR=0.91(95%CI 0.69-1.20,P=0.494);Sepsis-3 OR=0.80(95%CI 0.55-1.17,P=0.249)。
  • 90天死亡率比较:Sepsis-1定义下非脓毒性休克23.90%(38/159)vs. 脓毒性休克29.37%(126/429),P>0.05;Sepsis-3定义下22.72%(87/383)vs. 37.56%(77/205),P<0.01。
  • GAM模型验证结果与Logistic回归交叉验证一致。

证据类型、等级与局限

  • 证据类型:前瞻性观察队列研究的二次分析。
  • 证据等级或推荐强度:原文未提及。
  • 局限:二次分析;sCD73与死亡率的关系为观察性关联,不能推断因果;部分关联仅在趋势水平或特定定义下显著;需前瞻性验证。

对床旁实践的改变

  • 提示在解读sCD73与预后关系时,必须区分非脓毒性休克与脓毒性休克人群,两者关联方向相反。
  • 该关联为观察性趋势,不能作为床旁决策阈值或常规检测推荐;原文未提供sCD73的检测方法或干预措施。
  • 按Sepsis-3定义时脓毒性休克90天死亡率显著高于非脓毒性休克,按Sepsis-1定义则无差异,提示定义选择影响预后分层。

指南或共识出处

  • FINNAKI研究(芬兰急性肾损伤前瞻性观察研究)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: Fundamental researches have shown that soluble CD73 (sCD73) can inhibit inflammatory response and limit excessive tissue damage caused by continuous immune cell activation. A Finnish prospective, observational study of acute kidney injury (FINNAKI) showed no association between sCD73 and 90-day mortality in sepsis patients. Clinical data of this study was used for secondary analysis to explore whether the relationship between sCD73 and 90-day mortality was consistent in septic shock and non-septic shock patients.

METHODS: The FINNAKI study was a prospective, observational cohort study conducted in 17 intensive care units (ICUs) in Finland from September 1st, 2011 to February 1st, 2012. Sepsis/septic shock was defined according to Sepsis-1 definition. Demographic characteristics, treatment, comorbidities and 90-day mortality of the patients were analyzed. To evaluate the difference (interaction test) between the relationship of sCD73 and 90-day mortality in septic shock and non-septic shock patients, likelihood ratio test was used to integrate the product term (sCD73×septic shock or non-septic shock) into multivariable Logistic regression. Sensitivity analysis was performed with the definition of Sepsis-3. The interaction between sCD73 and 90-day mortality in patients with septic shock and non-septic shock were verified by generalized additive model (GAM).

RESULTS: A total of 588 patients with severe sepsis/septic shock were enrolled. 164 patients died in 90 days, and the 90-day mortality was 27.89%. Based on the Sepsis-1 definition, there were 159 non-septic shock patients and 429 septic shock patients. Compared with the non-septic shock patients, lactate (Lac) level, sequential organ failure assessment (SOFA) score, fluid balance on the first day, and ratio of mechanical ventilation, 12-hour acute kidney injury (AKI), renal replacement therapy (RRT), and postoperative ICU transition in the septic shock patients were significantly increased and the proportion of emergency admission to ICU was significantly decreased. Based on the Sepsis-3 definition, there were 383 non-septic shock patients and 205 septic shock patients; the results of clinical data analysis between the two groups were similar to those based on Sepsis-1. Based on Sepsis-1, there was no significant difference in 90-day mortality between non-septic shock and septic shock patients [23.90% (38/159) vs. 29.37% (126/429), P > 0.05]. However, based on Sepsis-3, the 90-day mortality of patients with septic shock was significantly higher than that of patients with non-septic shock [37.56% (77/205) vs. 22.72% (87/383), P < 0.01]. Multivariate Logistic regression analysis and interaction test showed that after adjusting all confounding factors (except the number of complications) in non-sepsis shock and sepsis shock patients, sCD73 and 90-day mortality were significantly different in both Sepsis-1 and Sepsis-3. The P values for interaction tests were 0.046 and 0.027, respectively. In patients with non-septic shock, sCD73 tended to be positively associated with 90-day mortality [Sepsis-1: odds ratio (OR) = 1.46, 95% confidence interval (95%CI) was 0.99-2.13, P = 0.053; Sepsis-3: OR = 1.34, 95%CI was 1.02-1.74, P = 0.034]. In septic shock patients, sCD73 tended to be negatively associated with 90-day mortality (Sepsis-1: OR = 0.91, 95%CI was 0.69-1.20, P = 0.494; Sepsis-3: OR = 0.80, 95%CI was 0.55-1.17, P = 0.249). The results of GAM model validation were consistent with the results of Logistic regression equation cross validation.

CONCLUSIONS: The relationship between sCD73 and 90-day mortality is significantly different from patients with non-sepsis shock and sepsis shock. In patients with non-sepsis shock, sCD73 is trend to positively associated with 90-day mortality, and there is a negative trend between sCD73 and 90-day mortality in patients with septic shock.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yang Q, Zhang Y, Kong T, et al. [The interaction between soluble CD73 and 90-day mortality from patients with non-septic shock and sepsis shock: a secondary analysis from the prospective FINNAKI study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33541493. doi:10.3760/cma.j.cn121430-20200417-00307

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。